SMC

Does the Patient Voice Really Impact Reimbursement?

Health Technology Assessment (HTA) agencies have been widely promoting their interest in taking relevant patient data into account during the drug review process. The effort to make a place for the patient voice in reviews is promising in an economic climate where the cost of innovation is under constant scrutiny. However, it raises two critical questions:

  • How much weight does the patient data have in the HTA decision process?
  • Are submissions by patient and professional groups associated with positive decisions? 

How Can the U.S. Healthcare System Better Measure Cost-Effectiveness?

The recent and frequent outcry over expensive drugs has made evident the gap in the United States’ healthcare system. While no perfect system exists, other countries have health technology assessment (HTA) agencies to evaluate efficacy and/or cost-effectiveness and inform reimbursement decisions.

What might the U.S. learn from countries like England, Germany, and France in structuring a methodology for evaluating drugs?